Breast Cancer Metastasis and Drug Resistance - Challenges and Progress (Paperback, 2nd ed. 2019)


Resistance to therapies, both targeted and systemic, and metastases to distant organs are the underlying causes of breast cancer-associated mortality. The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress. This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug resistance (bone metastasis, trastuzumab resistance, tamoxifen resistance and novel therapeutic targets, including non-coding RNAs, inflammatory cytokines, cancer stem cells, ubiquitin ligases, tumor microenvironment and signaling pathways such as TRAIL, JAK-STAT and mTOR) and recent developments in the field (epigenetic regulation, microRNAs-mediated regulation, novel therapies and the clinically relevant 3D models). Experts also discuss the advances in laboratory research along with their translational and clinical implications with an overarching goal to improve the diagnosis and prognosis, particularly that of breast cancer patients with advanced disease.

R4,346

Or split into 4x interest-free payments of 25% on orders over R50
Learn more

Discovery Miles43460
Mobicred@R407pm x 12* Mobicred Info
Free Delivery
Delivery AdviceShips in 10 - 15 working days



Product Description

Resistance to therapies, both targeted and systemic, and metastases to distant organs are the underlying causes of breast cancer-associated mortality. The second edition of Breast Cancer Metastasis and Drug Resistance brings together some of the leading experts to comprehensively understand breast cancer: the factors that make it lethal, and current research and clinical progress. This volume covers the following core topics: basic understanding of breast cancer (statistics, epidemiology, racial disparity and heterogeneity), metastasis and drug resistance (bone metastasis, trastuzumab resistance, tamoxifen resistance and novel therapeutic targets, including non-coding RNAs, inflammatory cytokines, cancer stem cells, ubiquitin ligases, tumor microenvironment and signaling pathways such as TRAIL, JAK-STAT and mTOR) and recent developments in the field (epigenetic regulation, microRNAs-mediated regulation, novel therapies and the clinically relevant 3D models). Experts also discuss the advances in laboratory research along with their translational and clinical implications with an overarching goal to improve the diagnosis and prognosis, particularly that of breast cancer patients with advanced disease.

Customer Reviews

No reviews or ratings yet - be the first to create one!

Product Details

General

Imprint

Springer Nature Switzerland AG

Country of origin

Switzerland

Series

Advances in Experimental Medicine and Biology, 1152

Release date

September 2020

Availability

Expected to ship within 10 - 15 working days

First published

2019

Editors

Dimensions

235 x 155 x 30mm (L x W x T)

Format

Paperback

Pages

427

Edition

2nd ed. 2019

ISBN-13

978-3-03-020303-0

Barcode

9783030203030

Categories

LSN

3-03-020303-4



Trending On Loot